Login to Your Account



BioMarin Also Takes a Hit

Genzyme Tumbles on FDA Lumizyme News

By Donna Young


Wednesday, March 4, 2009
Shares of Genzyme Corp. fell 7 percent Tuesday after the Cambridge, Mass.-based firm said it received a complete response letter from the FDA for its application for Pompe disease treatment Lumizyme (alglucosidase alfa), which is the 2,000 L bioreactor scale version of the firm's Myozyme. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription